Izuralimab clinical trials
Also written XmAb23104.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses izuralimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
Xencor, Inc. (1) · Memorial Sloan Kettering Cancer Center (1) · University of California, San Francisco (1)
Often tested with
Tested in the same studies.
Bavunalimab (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses izuralimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of XmAb23104 in People With SarcomaTerminatedPhase 2Memorial Sloan Kettering Cancer CenterNCT05879185Written as XmAb23104How we know
- XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor TherapyTerminatedPhase 1University of California, San FranciscoNCT05695898Written as XmAb23104How we know
- A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)CompletedPhase 1Xencor, Inc.NCT03752398Written as XmAb®23104How we know
Codes
What other systems call izuralimab · ClinicalTrials.gg INT015847
- UNII (FDA) 9D2R4T39AYIZURALIMABOne source FDA
- NCI Thesaurus C157578IzuralimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 9D2R4T39AY | IZURALIMAB | One source FDA |
| NCI Thesaurus | C157578 | Izuralimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.